Get the Stockscreener App
102.59
0.07%
-0.07
Biontech Se Adr stock is traded at $102.59, with a volume of 731.74K.
It is down -0.07% in the last 24 hours and down -8.12% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$102.66
Open:
$103.82
24h Volume:
731.74K
Relative Volume:
0.97
Market Cap:
$24.66B
Revenue:
$3.13B
Net Income/Loss:
$-381.72M
P/E Ratio:
-63.95
EPS:
-1.6042
Net Cash Flow:
$-2.15B
1W Performance:
+1.96%
1M Performance:
-8.12%
6M Performance:
-5.69%
1Y Performance:
+2.05%
1-Day Range:
$102.31
$104.40
1-Week Range:
$99.58
$114.89
52-Week Range:
$81.20
$131.49
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
102.59 | 24.68B | 3.13B | -381.72M | -2.15B | -1.6042 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.01 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
480.80 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.19 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
766.33 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
350.01 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
Baird Financial Group Inc. Has $1.13 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults - Benzinga
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - Ariva
Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday - Benzinga
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar
Pfizer and BioNTech: Slightly Lowering Our MRNA Vaccine Forecast Due to US Policy Headwinds - Morningstar
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
BioNTech SE Sponsored ADR $BNTX Shares Acquired by HighTower Advisors LLC - Defense World
Cresset Asset Management LLC Sells 1,035 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech’s Promising Phase III Study in Recurrent Endometrial Cancer - The Globe and Mail
BioNTech SE Sponsored ADR $BNTX Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
BioNTech’s Promising NSCLC Study: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
BioNTech’s Promising Phase III Study on Recurrent Endometrial Cancer - The Globe and Mail
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s Combined Vaccine Study: A Potential Game-Changer - TipRanks
BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
HC Wainwright Has Bearish Estimate for BioNTech Q3 Earnings - Defense World
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment - MSN
US Bancorp DE Cuts Stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s New Study on Breast Cancer Treatment: A Potential Game-Changer? - The Globe and Mail
BioNTech (NASDAQ:BNTX) Price Target Lowered to $136.00 at HC Wainwright - Defense World
BioNTech’s BNT113 Trial: A Potential Game-Changer in Head and Neck Cancer Treatment - TipRanks
BioNTech’s Latest Clinical Study: A New Hope for Advanced Breast Cancer Treatment - The Globe and Mail
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer? - TipRanks
BioNTech’s Promising Trial: BNT113 and Pembrolizumab in Head and Neck Cancer - The Globe and Mail
BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology - TipRanks
BioNTech’s BNT327 Study: A New Hope for Lung Cancer Treatment? - The Globe and Mail
BioNTech’s Promising Phase II Study on BNT327 for Small-cell Lung Cancer - The Globe and Mail
Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail
BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks
BioNTech SE’s BNT331 Safety Trial: A Potential Game-Changer in Women’s Health - TipRanks
Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech ADR Earns RS Rating Upgrade - Investor's Business Daily
BioNTech’s Strategic Moves and Financial Outlook - The Globe and Mail
BioNTech SE Earnings Call: Strategic Growth Amid Challenges - TipRanks
Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech Earnings: Guidance Reiterated; Incremental Progress in Clinical Trials - Morningstar
Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update04.08.25News - Ariva
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - The Globe and Mail
BioNTech (BNTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):